[go: up one dir, main page]

PL333370A1 - Method of using cyclo-oxygenase-2 inhibitors as agents acting against overgrowth of vessels - Google Patents

Method of using cyclo-oxygenase-2 inhibitors as agents acting against overgrowth of vessels

Info

Publication number
PL333370A1
PL333370A1 PL97333370A PL33337097A PL333370A1 PL 333370 A1 PL333370 A1 PL 333370A1 PL 97333370 A PL97333370 A PL 97333370A PL 33337097 A PL33337097 A PL 33337097A PL 333370 A1 PL333370 A1 PL 333370A1
Authority
PL
Poland
Prior art keywords
oxygenase
cyclo
vessels
inhibitors
acting against
Prior art date
Application number
PL97333370A
Other versions
PL191793B1 (en
Inventor
Jaime L Masferrer
Amiram Raz
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of PL333370A1 publication Critical patent/PL333370A1/en
Publication of PL191793B1 publication Critical patent/PL191793B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
PL333370A 1996-11-19 1999-04-30 Method of using cyclo-oxygenase-2 inhibitors as agents acting against overgrowth of vessels PL191793B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3140496P 1996-11-19 1996-11-19
PCT/US1997/021489 WO1998022101A2 (en) 1996-11-19 1997-11-19 Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents

Publications (2)

Publication Number Publication Date
PL333370A1 true PL333370A1 (en) 1999-12-06
PL191793B1 PL191793B1 (en) 2006-07-31

Family

ID=21859277

Family Applications (2)

Application Number Title Priority Date Filing Date
PL97373973A PL194717B1 (en) 1996-11-19 1997-11-19 Method of using cyclooxygenase-2 inhibitors as agents acting against overgrowth of vessels
PL333370A PL191793B1 (en) 1996-11-19 1999-04-30 Method of using cyclo-oxygenase-2 inhibitors as agents acting against overgrowth of vessels

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL97373973A PL194717B1 (en) 1996-11-19 1997-11-19 Method of using cyclooxygenase-2 inhibitors as agents acting against overgrowth of vessels

Country Status (19)

Country Link
EP (1) EP0941080A2 (en)
JP (1) JP2001505564A (en)
KR (1) KR20000053362A (en)
CN (1) CN1247470A (en)
AU (1) AU730211B2 (en)
BR (1) BR9713522A (en)
CA (1) CA2270469C (en)
CZ (1) CZ176899A3 (en)
ID (1) ID21979A (en)
IL (1) IL129604A (en)
NO (1) NO992309L (en)
NZ (1) NZ335853A (en)
PL (2) PL194717B1 (en)
RO (1) RO118566B1 (en)
RU (1) RU2268716C2 (en)
SK (1) SK59999A3 (en)
TR (1) TR199901703T2 (en)
UA (1) UA70294C2 (en)
WO (1) WO1998022101A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6512121B2 (en) 1998-09-14 2003-01-28 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US6515014B2 (en) 1995-06-02 2003-02-04 G. D. Searle & Co. Thiophene substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US6887893B1 (en) 1997-12-24 2005-05-03 Sankyo Company, Limited Methods and compositions for treatment and prevention of tumors, tumor-related disorders and cachexia
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US20030013739A1 (en) * 1998-12-23 2003-01-16 Pharmacia Corporation Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
AU2209800A (en) * 1998-12-23 2000-07-31 G.D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and radiation therapy as combination therapy in the treatment of neoplasia
EP1637137A3 (en) * 1999-03-10 2006-07-05 G.D. Searle LLC Method and composition for administering a cyclooxygenase-2 inhibitor to animals
ATE294574T1 (en) * 1999-07-29 2005-05-15 Tularik Inc COMBINATION THERAPY WITH PENTAFLUOROBENZENESULFONAMIDE AND PLATINUM DERIVATIVES
ES2243504T3 (en) * 2000-05-19 2005-12-01 Applied Research Systems Ars Holding N.V. USE OF PIRAZOL DERIVATIVES TO TREAT INFERTILITY.
AU2002234165A1 (en) 2000-11-03 2002-05-27 Tularik, Inc. Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
KR100686537B1 (en) * 2001-12-28 2007-02-27 씨제이 주식회사 Diaryl 1,2,4-triazole derivatives having excellent selectivity as inhibitors of cyclooxygenase-2
BR0312744A (en) * 2002-07-17 2005-04-26 Warner Lambert Co Combination of an allosteric carboxylic matrix metalloproteinase-13 inhibitor with a selective cyclooxygenase-2 inhibitor other than celecoxib or valdecoxib
KR100484525B1 (en) * 2002-10-15 2005-04-20 씨제이 주식회사 Isothiazole derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same
AT504159A1 (en) * 2006-08-16 2008-03-15 Marlyn Nutraceuticals Inc USE OF PROTEASES
RU2475257C1 (en) * 2011-06-22 2013-02-20 Людмила Николаевна Третьяк Preparation for increasing organism adaptability to extreme conditions
GB2496135B (en) * 2011-11-01 2015-03-18 Valirx Plc Inhibitors of the interaction between a Src family kinase and an androgen receptor or estradiol receptor for treatment of endometriosis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2297592A1 (en) * 1993-01-15 1994-07-21 G.D. Searle & Co. Novel 3,4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents
US5436265A (en) * 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
PT731795E (en) * 1993-11-30 2000-05-31 Searle & Co PYRAZOLYLBENZENESULFONAMIDES FOR THE TREATMENT OF INFLAMMATIONS
US5521213A (en) * 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
ES2191069T3 (en) * 1994-12-21 2003-09-01 Merck Frosst Canada Inc DIARIL-2- (5H) -FURANONAS AS COX-2 INHIBITORS.
US5691374A (en) * 1995-05-18 1997-11-25 Merck Frosst Canada Inc. Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors

Also Published As

Publication number Publication date
WO1998022101A2 (en) 1998-05-28
CA2270469A1 (en) 1998-05-28
JP2001505564A (en) 2001-04-24
NO992309D0 (en) 1999-05-12
CZ176899A3 (en) 1999-10-13
EP0941080A2 (en) 1999-09-15
CN1247470A (en) 2000-03-15
IL129604A (en) 2004-08-31
NO992309L (en) 1999-05-12
IL129604A0 (en) 2000-02-29
AU7298298A (en) 1998-06-10
KR20000053362A (en) 2000-08-25
PL191793B1 (en) 2006-07-31
UA70294C2 (en) 2004-10-15
ID21979A (en) 1999-08-19
BR9713522A (en) 2000-03-21
PL194717B1 (en) 2007-06-29
RU2268716C2 (en) 2006-01-27
WO1998022101A3 (en) 1998-06-25
CA2270469C (en) 2007-04-10
NZ335853A (en) 2002-02-01
AU730211B2 (en) 2001-03-01
TR199901703T2 (en) 2000-07-21
RO118566B1 (en) 2003-07-30
SK59999A3 (en) 2000-01-18

Similar Documents

Publication Publication Date Title
PL333370A1 (en) Method of using cyclo-oxygenase-2 inhibitors as agents acting against overgrowth of vessels
AU5896699A (en) Access system for branched vessels and methods of use
EP0519748A3 (en) Peptidyl derivatives as inhibitors of interleukin-1b converting enzyme
PL333918A1 (en) Derivatives of 6-phenylpyryidil-2-amine useful as nos inhibitors
PL327569A1 (en) Promedications of thrombosin inhibitors
PL331254A1 (en) Phosphonianic inhibitors of matrix metaloproteases
ZA9710907B (en) Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phospohorylase inhibitors
AU9214398A (en) Compositions and methods for treating water
SG67371A1 (en) Method of preventing pitting corrosion
AU6856496A (en) Compositions and methods for inhibiting corrosion
EP0781132A4 (en) Methods of inhibiting ulcerative mucositis
GB0029763D0 (en) System for elimination of audible effects of handover
AP2000001780A0 (en) Apparatus and method for the purification of water
PL333984A1 (en) Method of obtaining n-substituted 3-hydroxypyrazoles
HUP9904243A3 (en) Method for inhibiting the expression of fas
HUP0102259A3 (en) Methods of inhibiting corrosion using isomers of chloro-methylbenzotriazole
ZA9710989B (en) Polyprolyl inhibitors of cyclophilin
AU6422494A (en) Method for ultra-trace level analysis of water
PL333104A1 (en) Method of obtaining hydroxylammonia salts
IL143413A0 (en) Method for the activation of water and use thereof
GB2303660B (en) Apparatus for the combatting of underwater growth on submerged structures
HUT75696A (en) Procedure for making of water with low deuterium-content
PL322111A1 (en) Method of obtaining locarbeph monohydrate
GB9615262D0 (en) Method for inhibiting the growth of microorganisms in an aqueous medium
HU9701918D0 (en) Method and composition for removing of phosphor contain of water